Early diagnosis is key
Cancer is the second leading cause of death and is responsible for 1-in-6 deaths worldwide each year. It is widely accepted that the best way of tackling cancer is for patients to receive an early diagnosis, as this improves their chances of surviving cancer. Volition is developing simple, easy to use blood-based tests to diagnose a range of cancers and other diseases.
We believe that Nu.Q® will provide a low-cost routine blood test allowing doctors to check off an extra box along with other routine blood tests, such as cholesterol and PSA, during a single visit, and that this is currently the only credible way of taking compliance with screening above 80%.
“Screening increases the chances of detecting certain cancers early when they are most likely to be curable.”American Cancer Society
In the U.S. alone, one person dies of a cancer-related death every minute.
The ongoing problem
Cancer is the second leading cause of death worldwide with over 18.1 million new cases diagnosed each year. This causes over 9.6 million deaths worldwide and is expected to increase to over 16 million deaths by 2040.
Current cancer diagnosis involves expensive, unpleasant and, often, invasive testing. Using our Nu.Q® technology we aim to make cancer diagnosis as accessible as cholesterol or pregnancy testing.Dr. Jake Micallef, PhD, MBACSO
Rethinking the approach to cancer
Nu.Q® represents a powerful step change in rethinking the approach to cancer. It is a simple solution to the challenging problem of early cancer diagnosis.
Intellectual Property - covers human and veterinary applications
Believed to be the only company working on ELISA measurement for epigenetically modified circulating nucleosomes.
As of December 31, 2020: